1. From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco Cancer Center, University of California-San Francisco, San Francisco, California, and TAP Pharmaceutical Products, Inc. (JD), Lake Forest, Illinois